Fermented infant formula (with Bifidobacterium breve C50 and Streptococcus thermophilus O65) with prebiotic oligosaccharides is safe and modulates the gut microbiota towards a microbiota closer to that of breastfed infants
Ферментированная смесь для грудных детей (с Bifidobacterium breve C50 и Streptococcus thermophilus O65) с пребиотическими олигосахаридами безопасна и модифицирует кишечную микробиоту, приближая ее к микробиоте детей, находящихся на грудном вскармливании
2020-07-23
SCID: 54.1/msx6xts7
Discuss with AI
Bifidobacterium breve C50fermented infant formulagut microbiota modulationprebiotic oligosaccharidessecretory IgA
Figures from the paper
Abstract (AI)
BACKGROUND & AIMS: Microbiome-modulators can help positively steer early-life microbiota development but their effects on microbiome functionality and associated safety and tolerance need to be demonstrated. We investigated the microbiome impact of a new combination of bioactive compounds, produced by the food-grade microorganisms Bifidobacterium breve C50 and Streptococcus thermophilus ST065 during a fermentation process, and prebiotics in an infant formula. Tolerance and safety were also assessed. METHODS: An exploratory prospective, randomized, double-blind, controlled, multi-centre study was designed to investigate the effect of bioactive compounds and prebiotics (short-chain galacto-oligosaccharides (scGOS)/long-chain fructo-oligosaccharides (lcFOS) 9:1). Experimental formulas containing these bioactive compounds and prebiotics (FERM/scGOS/lcFOS), prebiotics (scGOS/lcFOS), or bioactive compounds (FERM), were compared to a standard cow's milk-based control formula (Control). Exclusively breastfed infants were included as a reference arm since exclusive breastfeeding is considered as the optimal feeding for infants. The study lasted six months and included visits to health care professionals at baseline, two, four and six months of age. Stool SIgA concentration was the primary study outcome parameter. RESULTS: There were 280 infants randomized over the experimental arms and 70 infants entered the breastfed-reference arm. Demographics were balanced, growth and tolerance parameters were according to expectation and adverse events were limited. At four months of age the median SIgA concentration in the FERM/scGOS/lcFOS group was significantly higher compared to the Control group (p = 0.03) and was more similar to the concentrations found in the breastfed-reference group. Bifidobacterium increased over time in all groups. The FERM/scGOS/lcFOS combination resulted in a microbiota composition and metabolic activity closer to the breastfed infants' microbiome. CONCLUSION: The FERM/scGOS/lcFOS combination showed a significant positive effect on SIgA levels. All formulas tested were associated with normal growth and were well-tolerated. Additionally, at four months of age the FERM/scGOS/lcFOS formula brought the microbiome composition and metabolic activity closer towards that of breastfed infants. CLINICAL TRIAL REGISTRY: Registration number NTR2726 (Netherlands Trial Register; www.trialregister.nl/).
Key Findings
1
A fermented infant formula containing compounds produced by Bifidobacterium breve C50 and Streptococcus thermophilus ST065 plus scGOS/lcFOS prebiotics was evaluated in a six-month randomized, double-blind, controlled multicenter study.
2
At four months, the fermented formula with scGOS/lcFOS produced significantly higher median stool SIgA than the control formula (p = 0.03), with values more similar to breastfed infants.
3
Bifidobacterium abundance increased over time across all formula and breastfed-reference groups.
4
Growth, tolerance, and adverse-event profiles were as expected, supporting the safety of the experimental formulas in the studied infants.
5
The fermented formula combined with scGOS/lcFOS shifted microbiota composition and metabolic activity closer to those observed in exclusively breastfed infants.
Research Object
Fermented infant formula containing bioactive compounds from Bifidobacterium breve C50 and Streptococcus thermophilus ST065 combined with prebiotic oligosaccharides (scGOS/lcFOS)
Research Subject
Safety, tolerance, and modulation of gut microbiota composition, metabolic activity, and stool SIgA toward profiles closer to those of breastfed infants
Publication Details
Publication Date
2020-07-23
Journal
Publisher
ISSN
Cited by
69
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai9
Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics2017
Colon Microflora in Infants Fed Formula with Galacto- and Fructo-Oligosaccharides: More Like Breast-Fed Infants2004
Colon Microflora in Infants Fed Formula with Galacto- and Fructo-Oligosaccharides: More Like Breast-Fed Infants2004
Quantitative Real-Time PCR Analysis of FecalLactobacillusSpecies in Infants Receiving a Prebiotic Infant Formula2006
Quantitative Real-Time PCR Assays To Identify and Quantify Fecal Bifidobacterium Species in Infants Receiving a Prebiotic Infant Formula2005
Effects of infant formula containing a mixture of galacto- and fructo-oligosaccharides or viable Bifidobacterium animalis on the intestinal microflora during the first 4 months of life2005
Effects of Long-term Consumption of a Fermented Infant Formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on Acute Diarrhea in Healthy Infants2004
Partly Fermented Infant Formulae With Specific Oligosaccharides Support Adequate Infant Growth and Are Well‐Tolerated2016
EARLY ADMINISTRATION OF GOS/FOS PREVENTS INTESTINAL AND RESPIRATORY INFECTIONS IN INFANTS2006
Cited by3
Preventive Effect of a Postbiotic and Prebiotic Mixture in a Rat Model of Early Life Rotavirus Induced-Diarrhea2022
Effects of a Postbiotic and Prebiotic Mixture on Suckling Rats’ Microbiota and Immunity2021
The Impact of Early Life Experiences and Gut Microbiota on Neurobehavioral Development in Preterm Infants: A Longitudinal Cohort Study2023